Mn Services Vermogensbeheer B.V. Buys 1,600 Shares of Becton, Dickinson and Company $BDX

Key Points

• Mn Services Vermogensbeheer B.V. increased its stake in Becton, Dickinson and Company by 1.5%, owning 107,304 shares valued at approximately $18.48 million at the end of the latest quarter.
• Becton, Dickinson and Company reported a quarterly earnings per share of $3.68, exceeding analysts' expectations of $3.40 by $0.28, with a revenue increase of 10.4% year-over-year.
• The company recently announced a quarterly dividend of $1.04 per share, representing an annual yield of 2.2% and a payout ratio of 74.82%.

Mn Services Vermogensbeheer B.V. lifted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 107,304 shares of the medical instruments supplier's stock after acquiring an additional 1,600 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Becton, Dickinson and Company were worth $18,483,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after acquiring an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Becton, Dickinson and Company by 3.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after buying an additional 448,644 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 10.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock worth $1,567,654,000 after purchasing an additional 667,957 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Becton, Dickinson and Company by 7.6% during the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock worth $1,012,649,000 after acquiring an additional 312,124 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Becton, Dickinson and Company by 1.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier's stock valued at $707,872,000 after purchasing an additional 37,733 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company's stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,965 shares of company stock worth $551,536. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

BDX traded down $1.10 during trading on Friday, reaching $187.27. 2,750,943 shares of the company's stock were exchanged, compared to its average volume of 1,535,837. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock has a market capitalization of $53.68 billion, a P/E ratio of 33.68, a price-to-earnings-growth ratio of 1.51 and a beta of 0.27. The company's fifty day simple moving average is $187.65 and its 200-day simple moving average is $190.16.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. During the same quarter last year, the company earned $3.50 EPS. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BDX shares. Piper Sandler reaffirmed a "neutral" rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Wells Fargo & Company increased their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Finally, Argus increased their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $213.30.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.